How race and ancestry influence breast cancer treatment responses
Official title: Race and ancestry as predictors of the tumor immune microenvironment and response to immunotherapy
Funded at University of California, San Francisco · NIH-10880147 · Data updated 2026-11-12
This study is looking at how different racial and ethnic backgrounds influence how well women with triple-negative breast cancer respond to immunotherapy, aiming to understand treatment differences among Black, Hispanic/Latina, and Asian women to help improve care for everyone.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $369,354 |
| NIH project number | 1P20CA290477-01 |
| Project ID | NIH-10880147 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include women diagnosed with triple-negative breast cancer, particularly those from Black, Hispanic/Latina, and Asian backgrounds.
✕Less likely to help
Patients with non-breast cancer diagnoses or those not belonging to the specified racial and ethnic groups may not benefit from this research.
What this research studies
This research investigates how different racial and ethnic backgrounds affect the immune response to breast cancer treatments, particularly immunotherapy. It focuses on understanding the tumor immune microenvironment in women with triple-negative breast cancer (TNBC), a type that is more responsive to these treatments. By analyzing population-based cancer registry data, the study aims to determine the frequency of immunotherapy use among diverse groups, including Black, Hispanic/Latina, and Asian women. The goal is to uncover disparities in treatment outcomes and improve personalized care for these populations.
Why it matters
Potential benefit: If successful, this research could lead to more effective and tailored immunotherapy treatments for breast cancer patients from diverse racial and ethnic backgrounds.
How similar studies have gone: Previous research has indicated that understanding the tumor immune microenvironment can significantly impact treatment outcomes, suggesting that this approach has potential for success.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Ziv, Elad — University of California, San Francisco
- Study coordinator: Ziv, Elad
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.